Europe expansion OM1 has recently expanded its offices into Europe in March 2025, signaling a growing regional footprint and potential sales opportunities with European pharmaceutical and healthcare organizations seeking AI-enhanced RWE solutions.

AI platform depth OM1’s patented AI platform powering personalized medicine and real-world evidence analytics, along with offerings like PhenOM, Orion, Lyra and Polaris, suggests opportunities to upsell advanced AI-driven data services and clinical trial personalization for sponsors and payers.

Clinical datasets New clinical datasets such as Chronic Rhinosinusitis and Asthma indicate a focus on disease-specific real-world evidence, presenting entry points for collaboration with specialty pharma, CROs, and payer initiatives in those domains.

Regulatory-grade data With emphasis on regulatory-grade deep longitudinal data and RWE from bench-to-practice, OM1 appeals to payers and regulators seeking high-integrity evidence to support value-based care decisions and regulatory submissions.

Industry recognition Award attention and leadership hires, including Frost & Sullivan recognition and experienced GM appointment, reinforce OM1’s credibility for large-scale partnerships and multi-country deployments with global life sciences clients.